Westlake Epoxy Unveils EpoVIVE™ Portfolio at ECS 2025: A New Era of Sustainable Solutions
24.3.2025 21:52:00 CET | Business Wire | Press release
Westlake Corporation (NYSE: WLK) announced today that Westlake Epoxy plans to launch several new products at the European Coatings Show (ECS) 2025, March 25 to 27, 2025, in Germany. Westlake Epoxy will be showcasing at booth # 5-349 its latest innovations designed to enhance robustness, safety, and performance.
At Westlake, we challenge ourselves to do more, to go further in our quest for improved sustainability. As such we strive to develop new technologies that help support customer sustainability initiatives. We are proud to present at ECS our newly introduced EpoVIVE™ portfolio of products that provide sustainability advantages as compared to traditional Westlake formulas in one or more of the following categories:
- Lower Carbon Footprint: Utilize ISCC PLUS mass-balanced bio circular or circular raw materials to reduce carbon emissions.
- Energy Efficiency: Combine renewable energy with energy-efficient practices to reduce the carbon footprint.
- Safer Materials: Use of safer materials that are free from SVHC (substances of very high concern) and CMR (carcinogenic, mutagenic and reprotoxic), improving safe handling.
- Emission Reductions: Achieve lower VOC (volatile organic compounds) waterborne epoxy resin dispersions, contributing to the reduction of VOC emissions during customer applications.
- More Circular Solutions: Support improved circularity with innovative formulations and recycling processes that allow for enhanced ability to reuse, recycle, or repurpose products in the EpoVIVE™ portfolio.
Designed to meet the increasing demand for low-emission, and SVHC-free alternatives that use bio-circular or circular materials, these cutting-edge products offer enhanced durability, corrosion protection, and ease of use while improving our environmental footprint through operational innovations and product offerings with reduced environmental impacts.
The EpoVIVE™ range introduces NEW EPIKOTE™ Resins 901 and 902, providing CMR-free alternatives to conventional C12-C14 diluted resins for high-performance flooring. The portfolio also features the AQUAREOUS™ epoxy systems enabling lower volatile organic compound (VOC), solvent-free coatings for concrete and metal, while SVHC-free AZURES™ products deliver CMR free labelled, high-performance solutions for coatings, civil engineering, and adhesives.
In addition to the EpoVIVE™ portfolio, Westlake Epoxy will introduce the ENABLING Curing Agent EPIKURE™ 6874-WZ-50, which simplifies waterborne formulations and enhances corrosion protection for smooth steel.
"Our commitment to improved sustainability drives us to continuously innovate and deliver solutions that help our customers meet their environmental and performance goals. The launch of the EpoVIVE™ portfolio and related product developments reflect Westlake Epoxy's dedication to reducing the environmental impact of our products while maintaining our high standards of quality and performance," said Karl-Martin Schellerer, Westlake Senior Vice President — Performance and Essential Materials, Europe and Asia.
To learn more about EpoVIVE™ products and Westlake Epoxy’s new innovations for the coatings industry, we invite you to participate in the presentations “New Low labelled Resin Blends for Epoxy Flooring Applications” presented by Patrick Deudon, on Tuesday, March 25th at 14:30 – 14:50, booth # 3-742, Hall 3, and “Novel Waterborne Epoxy Systems: Boosting your Coating Performance”, presented by Dominique Vandenberghe, on Wednesday, March 26th at 13:50 – 14:10, booth # 5-243, Hall 5.
Westlake Epoxy aspires to continuously improve its Environmental, Sustainable and Governance journey. Westlake Epoxy is committed to reducing its carbon footprint through purposefully sourcing more sustainable raw materials, and refining and improving manufacturing processes. Together, we are enhancing your life every day!
About Westlake
Westlake Corporation (NYSE: WLK) is a global manufacturer and supplier of materials and innovative products that enhance life every day. Headquartered in Houston, with operations in Asia, Europe, and North America, we provide the building blocks for vital solutions — from housing and construction, to packaging and healthcare, to automotive and consumer. For more information, visit the company's web site at www.westlake.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250324929717/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 15:37:00 CEST | Press release
The new SpeechLive Legal AI Assistant reduces the administrative burden on legal professionals through customizable document drafting powered by speech recognition tuned for legal terminology Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom